Reviewed by Mr. Hugh Mostafid (Royal Surrey County Hospital, Guildford, UK) UTUC: similarities and differences compared to bladder cancer While bladder tumours account for 90-95% of all urothelial carcinomas (UCa), only 5-10% of UCa cases involve the upper urinary...
Urinary biomarker tests, including Bladder EpiCheck®, are reimbursed from January 2024 in the Netherlands Reviewed by Prof. Joost Boormans (Erasmus MC Cancer Institute, Rotterdam, The Netherlands) Pitfalls of the current standard for NMIBC follow-up Due to the high...
The World Bladder Cancer Patient Coalition hosts this special month to raise awareness of the disease. The theme of this year’s edition “Feeling unsure? Get checked.” is to bring attention to the misrepresentation of symptoms and to encourage people to re-evaluate...
The World Bladder Cancer Patient Coalition hosts this special month to highlight the facts about bladder cancer, promote awareness of the disease and call for more investment in research, treatment and care. The theme of this year’s edition “Don’t Go Red. Go To A...
Reviewed by Professor Jørgen Bjerggaard Jensen (Aarhus University Hospital, Aarhus, Denmark) “A strategy alternating the urine marker Bladder EpiCheck® with cystoscopy in the surveillance of patients with low-grade intermediate-risk bladder cancer is cost-equivalent...
Reviewed by Morgan Rouprêt, Professor at the AP-HP Sorbonne University in the Academic Urology Department of the Pitié-Salpêtrière Hospital, Paris, France. Prof. Rouprêt is a panel member of the European Guidelines for non-muscle invasive bladder cancer (NMIBC)....
Recent Comments